Video

Dr. Modest on Study of Surgical Intervention in CRC

Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer.

Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer (mCRC).

In a central evaluation for surgical treatment options in the FIRE-3 study results, a panel of 8 surgeons and 3 medical oncologists served as reviewers of 448 patients, defining resectability as at least 50% of the reviewers recommending surgical intervention.

Findings showed that roughly 20% of the population would have been a candidate for surgical intervention and at best response, it was a little more than 50%, says Modest.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
R. Lor Randall, MD, FACS
Joshua Richter, MD of Tisch Cancer Institute
Guenther Koehne, MD, deputy director and chief of Stem Cell Transplantation, Hematologic Oncology and Benign Hematology at Miami Cancer Institute, Baptist Health South Florida
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
Bradley McGregor, MD
Katherine L. Nathanson, MD
Daniel J. DeAngelo, MD, PhD, chief of the Division of Leukemia and an institute physician at Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School
Julie M. Vose, MD, MBA
6369343864112
Matthew Wagar, MD of the University of Wisconsin School of Medicine and Public Health